CARD9 attenuates Aβ pathology and modifies microglial responses in an Alzheimer’s disease mouse model
Proceedings of the National Academy of Sciences · 2023
DOI: 10.1073/pnas.2303760120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Hannah Ennerfelt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Center for Brain Immunology and Glia, University of Virginia, Charlottesville, VA 22908. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases, Amyloidosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIGMS NIH HHS, NINDS NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Recent advances have highlighted the importance of several innate immune receptors expressed by microglia in Alzheimer’s disease (AD). In particular, mounting evidence from AD patients and experimental models indicates pivotal roles for TREM2, CD33, and CD22 in neurodegenerative disease progression. While there is growing interest in targeting these microglial receptors to treat AD, we still lack knowledge of the downstream signaling molecules used by these receptors to orchestrate immune responses in AD. Notably, TREM2, CD33, and CD22 have been described to influence signaling associated with the intracellular adaptor molecule CARD9 to mount downstream immune responses outside of the brain. However, the role of CARD9 in AD remains poorly understood. Here, we show that genetic ablation of CARD9 in the 5xFAD mouse model of AD results in exacerbated amyloid beta (Aβ) deposition, increased neuronal loss, worsened cognitive deficits, and alterations in microglial responses. We further show that pharmacological activation of CARD9 promotes improved clearance of Aβ deposits from the brains of 5xFAD mice. These results help to establish CARD9 as a key intracellular innate immune signaling molecule that regulates Aβ-mediated disease and microglial responses. Moreover, these findings suggest that targeting CARD9 might offer a strategy to improve Aβ clearance in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Center for Brain Immunology and Glia, University of Virginia, Charlottesville, VA 22908.
- Neuroscience Graduate Program, University of Virginia, Charlottesville, VA 22908.
- Cell and Molecular Biology Graduate Training Program, University of Virginia, Charlottesville, VA 22908.
- Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA 22908.
- Medical Scientist Training Program, University of Virginia, Charlottesville, VA 22908.
- Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53705.
ORCID-Profile: John R Lukens
Förderung
- NIA NIH HHS
- NIGMS NIH HHS
- NINDS NIH HHS
- NIAID NIH HHS
- The National Institutes of Health
- The Alzheimer's Association
- the Cure Alzheimer's Fund
- Owens Family Foundation
Zitieren
APA
Ennerfelt, H., Holliday, C., Shapiro, D. A., Zengeler, K. E., Bolte, A. C., Ulland, T. K., & Lukens, J. R. (2023). CARD9 attenuates Aβ pathology and modifies microglial responses in an Alzheimer’s disease mouse model. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2303760120
Vancouver
Ennerfelt H, Holliday C, Shapiro DA, Zengeler KE, Bolte AC, Ulland TK, et al. CARD9 attenuates Aβ pathology and modifies microglial responses in an Alzheimer’s disease mouse model. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2303760120
BibTeX
@article{Ennerfelt2023,
author = {Ennerfelt, Hannah and Holliday, Coco and Shapiro, Daniel A and Zengeler, Kristine E and Bolte, Ashley C and Ulland, Tyler K and Lukens, John R},
title = {CARD9 attenuates Aβ pathology and modifies microglial responses in an Alzheimer’s disease mouse model},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
doi = {10.1073/pnas.2303760120}
}
EUVIMED